Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 9/4/24 → 9/4/27 |
Financiación
- OncoVerity Incorporated: 84.678,00 US$
24-LEUK-26-OV (OV-AML-1231): A Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy
- Qasrawi, Ayman (PI)